Without chemotherapy, the average survival in patients with advanced CRC is 6 months, after the use of 5-fluorouracil (5FU), Irinotecan and Oxaliplatin this survival extended to 21 months though these new drugs have tripled the cost of treatment in these patients. Even though Cetuximab has shown some benefits in some disease clinical control parameters, it has not been already proven that it can improve survival; however, it is covered by some United States health organizations. Despite a higher number of therapeutic choices, the treatment of advanced CRC still remains palliative, with no evidence that new therapies can increase cure rate. The high cost of the new treatments forces to critically assess their results as regards resources available in health organizations.